Plain-English translation of NCT06715514 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether using semaglutide—a medication that helps control blood sugar and supports weight loss—works better when combined with hormone therapy in women who have recently gone through menopause. You may know semaglutide by brand names like Wegovy or Ozempic. The researchers want to understand if restoring estrogen levels through hormone therapy helps this medication work more effectively for managing blood sugar and weight in women with diabetes or at risk of developing it.
After menopause, many women struggle with blood sugar control and weight gain because estrogen levels drop. While this treatment has shown promise separately, doctors don't yet know whether combining these two approaches could work better together to help women manage their health during this life stage.
You would be randomly assigned to receive either semaglutide alone, hormone therapy alone, or both treatments combined. If you receive hormone therapy, you would wear a small patch that delivers estrogen and take a daily progesterone pill (if you still have your uterus). If you receive semaglutide, you would give yourself a small injection once a week, with the dose gradually increasing over 8 weeks. Throughout the study, you would have regular clinic visits to have your blood sugar, weight, and other health markers checked, and to discuss how you're feeling on the treatment.
AI-generated summary from trial data · Aug 16, 2026 · Not medical advice
Switzerland